Saghmos Therapeutics Inc., a Greenwich-based biopharmaceutical company focused on developing therapies for life-threatening cardiovascular and renal diseases, has named Fred Hassan as chairman of the board of directors.
Hassan is the former chairman of the board and CEO of Schering-Plough Corp. before its acquisition by Merck. Previously, he was chairman and CEO of Pharmacia Corp. before its acquisition by Pfizer. Prior to that, he was executive vice president of Wyeth, with responsibility for its pharmaceutical and medical products business and also headed the U.S. pharmaceuticals business at Sandoz Pharmaceuticals (now Novartis).
Hassan is chairman of Caret Group and a director at Warburg Pincus, a private equity firm. He is currently a board member of Precigen, BridgeBio and Cocrystal and was on the board of Prometheus Biosciences before its acquisition by Merck in June 2023. Previously, he was also on the boards of Amgen and Time Warner until its acquisition by AT&T, and was chairman of the boards of Avon Products and Bausch & Lomb.
“We are honored and privileged to work with Fred Hassan. His wealth of pharmaceutical industry experience and his guidance will tremendously benefit our mission to bring ST-62516 to patients,” said Dr. Anna Kazanchyan, founder and CEO of Saghmos.
